对托法西提尼布和甲铁酸盐的关节水平反应:对ORAL Start数据的后期分析
Adrian Ciurea1, Oliver Distler1, Kenneth Kwok2
1Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
Arthritis research & therapy
|September 29, 2023
概括
在风湿性关节炎 (RA) 患者中,托法西提尼布对大多数关节的临床反应比甲状腺素更好. 然而,甲索特酸导致脚关节的放射性进展变得更糟,这表明特定地点的治疗变化.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 类风湿性关节炎 (RA) 对突关节的影响有所变化.
- RA 病理生理学的解剖学差异可能导致不同的治疗反应.
- 分析了对托法西提尼布和甲铁沙特单独治疗的关节特异性反应.
研究的目的:
- 在RA患者中对托法西提尼布和甲铁酸的关节特异性反应的特征.
- 为了比较托法西提尼布和甲铁酸盐在不同关节部位的疗效.
- 评估这些治疗对放射性进展的影响.
主要方法:
- 对ORAL Start第三阶段试验的后期分析 (NCT01039688).
- 使用配对关节病理学得分 (PJPS) 和修改总利得分.
- 在3,6和12个月的PJPS和放射性进展的计算百分比变化.
主要成果:
- 在大多数关节中,托法西替尼比甲铁酸的PJPS比例大.
- 在脚关节中观察到对托法西提尼布的反应较小,特别是在12个月.
- 甲托雷克萨特治疗导致足部和手足后关节的放射性进展明显恶化.
结论:
- 对托法西提尼布和甲铁沙特单独治疗的关节特异性反应各不相同.
- 观察到近端-遥远的疗效梯度,脚的临床反应更好.
- 尽管有临床反应,但甲状腺导致了比托法西替尼更多的脚关节放射性进展.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
164
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
164
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
186
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
186
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
144
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
144
Drugs for Treatment of Ulcerative Colitis in IBD
164
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
164
Phase II Reactions: Methylation Reactions
220
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
220
Inflammatory Bowel Disease IV: Pharmacological Management
145
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
145


